Market capitalization | $101.94m |
Enterprise Value | $222.47m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.24 |
P/S ratio (TTM) P/S ratio | 4.69 |
P/B ratio (TTM) P/B ratio | 0.25 |
Revenue growth (TTM) Revenue growth | 322.60% |
Revenue (TTM) Revenue | $21.73m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a bluebird bio, Inc. forecast:
10 Analysts have issued a bluebird bio, Inc. forecast:
Sep '23 |
+/-
%
|
||
Revenue | 22 22 |
323%
323%
|
|
Gross Profit | -3.45 -3.45 |
60%
60%
|
|
EBITDA | -327 -327 |
25%
25%
|
EBIT (Operating Income) EBIT | -331 -331 |
25%
25%
|
Net Profit | -91 -91 |
80%
80%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Andrew Obenshain |
Founded | 1992 |
Website | www.bluebirdbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.